CVS Health is the largest US pharmacy chain with ~9,000 stores and an investment-grade BBB credit profile. The brand is in the final phase of a 1,170-store closure program targeting density overlap — surviving locations are the keepers. NNN cap rates currently span 6.25-6.75% on 10-15 year remaining terms; new 20+ year corporate-guaranteed ground leases trade sub-6%.

Pros:

• Highest-credit pharmacy NNN tenant (BBB IG)
• Corporate guarantee on every site — no franchise risk
• 1,170-store closure cohort largely complete; survivors are keepers
• Long primary terms (20-25 years) with options

Cons:

• Front-store retail weakness pressuring revenue mix
• Aetna integration drag flagged by rating agencies
• Moody’s downgraded to Baa3 in Dec 2024; S&P + Fitch negative outlooks
• Final 270 closures in 2025 — verify your asset is not on the list

CVS Health is the largest US pharmacy chain by store count (~9,000 locations after closures) and the highest-credit pharmacy NNN tenant available. With Rite Aid liquidated and Walgreens now owned by Sycamore Partners under heavy leverage, CVS stands alone as the BBB investment-grade pharmacy operator — and that scarcity premium continues to drive demand for CVS NNN product.

CVS is in the final phase of a 1,170-store realignment program announced in late 2021. Roughly 900 stores closed between 2022 and 2024; another 270 are scheduled to close in 2025. Closures have been driven by population shifts and store/pharmacy density overlap rather than industry pressure. CVS says 85% of Americans will still live within 10 miles of a CVS after the program completes. For NNN landlords, the practical implication is that properties surviving the 2022-2024 cohort are in the keep-list — but the final 270-store 2025 cohort is the open variable to underwrite.

CVS does not franchise. Every NNN lease is guaranteed directly by CVS Health (or a CVS Pharmacy subsidiary) — among the cleanest credit structures in net lease. Typical leases are 20-25 year primary terms with 7.5-10% bumps every 5-7.5 years on standalone, corporate-guaranteed boxes of 10,000-13,500 square feet on 1.0-1.5 acres. New 20+ year ground leases continue to trade sub-6% cap; older 10-15 year remaining inventory trades 6.25-6.75%.

Beyond the closure realignment, CVS is shifting capital from raw store expansion toward primary-care acquisitions (Oak Street Health), Medicare Advantage growth, and HealthHUB conversions. New CVS formats include smaller-footprint pharmacies under 5,000 SF, in-Target counters, and stores with built-in primary care services. Net footprint contraction of 2-3% is expected through 2027, offset by higher revenue per square foot at surviving locations.

Rating agencies have flagged credit migration risk: Moody’s downgraded CVS to Baa3 (one notch above junk) in December 2024 citing Medicare Advantage margin pressure and Aetna integration drag. S&P and Fitch maintained BBB but both with negative outlooks. CVS retains investment-grade status, but underwriters should be aware that the credit cushion is thinner than two years ago — and Senate Finance Committee scrutiny of PBM practices remains an ongoing tail risk.